Diaceutics launches diagnostic network platform for labs

LabPulse.com staff writers
May 17, 2020
2020 04 28 19 25 1337 Sequencing Dna Rna Pcr 400

Diaceutics is set to launch a diagnostic network platform that will support laboratories' efforts to provide precision medicine.

The platform, called DXRX -- The Diagnostic Network, will be launched in the fourth quarter of this year, the company said. The company plans to invest $28 million in software and data development toward the platform, which will connect more than 2,500 laboratories into a worldwide network.

Latest in Consumer
2019 05 17 20 09 8391 Hpv 400
Enzo launches RNA gene expression platform for HPV
September 25, 2022
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
May 11, 2023
2019 04 24 17 43 1766 Hands Shaking2 400
Precipio announces agreement to promote HemeScreen platform
September 15, 2022
2021 02 24 22 29 5379 Breast Cancer 20210224225528 20220322220342
Ibex announces study results for breast pathology platform
September 8, 2022
Related Stories
2017 09 14 23 05 1167 Cancer Cell 400
Breast Cancer
Caris to highlight precision medicine at ASCO 2020
2020 04 28 19 25 1337 Sequencing Dna Rna Pcr 400
Companion Diagnostics
Caris brings precision medicine assays closer to market
2020 03 20 23 56 2886 Artificial Intelligence Face 400
Artificial Intelligence
Clinical diagnostics and the artificial intelligence boom
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Consumer
Enzo launches RNA gene expression platform for HPV
The platform's products combine sequence-specific probes with Enzo's LoopRNA in situ hybridization (ISH) technology, enabling the products to detect target genes in tissue or cell samples while preserving the morphology, Enzo said. This study of single cells within their native tissue environment, called spatial biology, helps scientists characterize and understand disease, Enzo added.
September 25, 2022
2019 05 17 20 09 8391 Hpv 400
Glucose testing market to reach $27.1B by 2027: Kalorama
With a compound annual growth rate (CAGR) anticipated at 5.9%, the market is expected to reach $27.1 billion by 2027, said the report published by LabPulse.com's sister brand Kalorama Information.
September 18, 2022
2022 09 13 21 47 8940 Diabetes Woman Lancet 400
Precipio announces agreement to promote HemeScreen platform
The distributor focuses on a segment of the healthcare business which by Precipio's estimates represents an additional $100 million of market potential that its current distributors are less likely to reach.
September 15, 2022
2019 04 24 17 43 1766 Hands Shaking2 400
Ibex announces study results for breast pathology platform
Ibex chief medical officer Dr. Judith Sandbank reported at the congress 100% sensitivity and specificity for pathologists diagnosing breast cancer using the platform.
September 8, 2022
2021 02 24 22 29 5379 Breast Cancer 20210224225528 20220322220342
Freenome launches study of multiomics cancer platform
The Sanderson Study will generate evidence of clinical validation for certain high- and elevated-risk populations while refining the platform's cancer classification and risk prediction models, the South San Francisco-based firm said.
September 5, 2022
2022 08 08 21 26 6857 Lung Cancer2 400
Bruker launches new nano-LC chromatography platform
The platform includes MetaboScape and TASQ 2023 software to support fluxomics, as well as the PaSER database search platform's tools for research in protein-protein interactions and metaproteomics applications, the company said.
August 28, 2022
2022 08 29 21 03 5189 Nanoelute 2 Image 400
Boosted by COVID-19 and cancer tests, IVD market reaches $127B: Kalorama
That's the finding from Kalorama's market research report, The Worldwide Market for In Vitro Diagnostics, 15th edition.
August 25, 2022
2020 02 06 18 18 1550 Business Financial Results 400
Mainz Biomed, Dante Genomics expand ColoAlert availability
ColoAlert, Mainz Biomed's flagship product, will be marketed through Dante's database and sold through its region-specific e-commerce websites.
August 15, 2022
2019 11 04 19 56 0311 Colorectal Cancer 400
OraSure Technologies Q2 revenues rise on COVID testing
For the quarter ended June 30, the Bethlehem, PA-based company reported revenues of $80.2 million compared to $57.2 million in Q2 2021, beating analysts' average estimate of $70.1 million.
August 8, 2022
2020 05 01 17 12 0119 Antigen Tcell Cytokines 400
Video from AACC: BrightInsight's Connected Diagnostics Platform
Dr. Kal Patel, CEO and co-founder, and Andrea Curtis, director of in vitro diagnostics product management, sat down with ScienceBoard.net's sister site LabPulse.com to discuss how the platform enables greater product innovation, new revenue streams, and streamlined workflows.
July 27, 2022
2022 07 28 15 39 8857 Patel And Curtis 400
BrightInsight launches digital diagnostics platform at AACC
The platform consists of four tools -- Proxy Agent, Analytics Dashboards, Integration Middleware, and Workflow Portals -- for the IVD manufacturer and the lab, providing an end-to-end platform that streamlines workflows, according to BrightInsight.
July 24, 2022
2022 07 25 17 54 5379 Globe Digital 400
Companies announce new products ahead of AACC 2022
Among them, OraSure Technologies said that its Omnigene Gut DNA and RNA product is available to gut microbiome researchers. The product, made by OraSure subsidiary DNA Genotek, allows for self-collection, stabilization, storage, and transportation of both microbial DNA and RNA at ambient temperature for gut microbiome profiling.
July 21, 2022
2021 09 27 17 08 8174 Diagnostic Analyzer Lab Pcr 400
Page 1 of 8
Next Page